Cytosorbents (CTSO) Cash & Current Investments (2016 - 2026)
Cytosorbents filings provide 16 years of Cash & Current Investments readings, the most recent being $6.2 million for Q4 2025.
- On a quarterly basis, Cash & Current Investments fell 24.53% to $6.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $6.2 million, a 24.53% decrease, with the full-year FY2025 number at $6.2 million, down 24.53% from a year prior.
- Cash & Current Investments hit $6.2 million in Q4 2025 for Cytosorbents, down from $7.5 million in the prior quarter.
- In the past five years, Cash & Current Investments ranged from a high of $68.5 million in Q1 2021 to a low of $1.7 million in Q2 2023.
- Median Cash & Current Investments over the past 5 years was $12.9 million (2023), compared with a mean of $23.8 million.
- Biggest five-year swings in Cash & Current Investments: crashed 94.36% in 2023 and later soared 397.57% in 2024.
- Cytosorbents' Cash & Current Investments stood at $52.1 million in 2021, then tumbled by 57.53% to $22.1 million in 2022, then crashed by 36.19% to $14.1 million in 2023, then crashed by 41.41% to $8.3 million in 2024, then decreased by 24.53% to $6.2 million in 2025.
- The last three reported values for Cash & Current Investments were $6.2 million (Q4 2025), $7.5 million (Q3 2025), and $10.2 million (Q2 2025) per Business Quant data.